Indeed, developing selective natural (ET-743, sulforaphane, coumestrol) and synthetic (ketoconazole and its derivatives) PXR antagonists appears to be a reasonable approach for managing PXR-related adverse DDIs and cancer drug resistance [94]. The gene discussed is NR1I2; the disease is cancer.